Cambridge Investment Research Advisors
PRME icon

Cambridge Investment Research Advisors’s Prime Medicine PRME Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61K Buy
16,427
+4,090
+33% +$13.6K ﹤0.01% 3972
2026
Q1 		$43K Buy
+12,337
New +$47K ﹤0.01% 3868

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Cambridge Investment Research Advisors's PRME Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Prime Medicine (PRME) stake by 33% in Q2 2026, buying an estimated $13.6K and bringing the position to 16,427 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #3972.

Cambridge Investment Research Advisors first reported a position in PRME in Q1 2026 and has held it in 2 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Cambridge Investment Research Advisors held 16,427 shares of Prime Medicine worth $61K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 4,090 Prime Medicine shares in Q2 2026, an estimated $13.6K.
  • Prime Medicine made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3972 holding.
  • Cambridge Investment Research Advisors first reported a position in Prime Medicine in Q1 2026 and has held it in 2 quarters since.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.